Donald J. Santel - 06 Jun 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
AVTE
Transactions as of
06 Jun 2023
Transactions value $
$0
Form type
4
Date filed
08 Jun 2023, 18:00
Previous filing
23 Jan 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +12.5K $0.00 12.5K 06 Jun 2023 Common Stock 12.5K $16.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 6, 2024 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.